See analyst estimates and all valuation multiples for Genomics & Personalized Medicine
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $20.7B | 11.4x | -85.5x | |
| $14.4B | 3.3x | 12.5x | |
| $12.4B | 4.3x | 33.3x | |
| $5.6B | 7.1x | -23.2x | |
| $2.5B | 4.5x | 80.1x | |
| $2.1B | 2.4x | 13.6x | |
| $2.0B | 6.0x | 84.9x | |
| $1.8B | 4.0x | 18.6x | |
| $1.6B | 4.4x | -11.3x | |
| $949M | 1.5x | 16.1x | |
| $827M | 1.4x | -5.4x | |
| $771M | 5.7x | -0.7x | |
| $745M | 2.1x | 25.3x | |
| $644M | 4.2x | -3.0x | |
| $599M | 2.0x | 11.3x | |
| $524M | 66.9x | -5.7x | |
| $454M | 0.5x | 13.9x | |
| $425M | 6.7x | n/a | |
| $318M | 1.1x | -31.0x | |
| $291M | n/a | n/a | |
| $268M | 3.2x | -3.9x | |
| $259M | 24.9x | n/a | |
| $241M | 106.7x | -13.9x | |
| $240M | 70.2x | n/a | |
| $239M | 48.5x | -61.5x | |
| $225M | n/a | n/a | |
| $212M | 0.7x | 4.6x | |
| $163M | 2.4x | -4.0x | |
| $158M | 1.1x | -0.7x | |
| $158M | n/a | n/a | |
| $132M | 18.9x | -0.7x | |
| $118M | 24.6x | -0.6x | |
| $114M | 2.0x | -1.6x | |
| $56.4M | 82.3x | -0.3x | |
| $38.3M | 14.9x | n/a | |
| $36.4M | n/a | -0.4x | |
| $35.0M | 0.7x | 5.4x | |
| $16.8M | n/a | n/a | |
| $12.4M | 0.4x | -0.2x | |
| $8.0M | n/a | n/a | |
| $7.4M | n/a | -0.1x | |
| $6.1M | 0.1x | -0.2x | |
| $3.1M | 0.1x | -0.0x | |
| $16K | n/a | -0.0x | |
| -$0.4M | n/a | 0.0x | |
| -$1.8M | -1.4x | 0.0x | |
| -$2.7M | n/a | n/a | |
| -$11.1M | n/a | n/a | |
| -$30.9M | -0.8x | 0.1x | |
| -$35.6M | n/a | 0.2x | |
| -$43.0M | -0.7x | 0.4x | |
| -$44.8M | -2.5x | n/a | |
| -$45.4M | -1.8x | 0.2x | |
| -$67.2M | -1.4x | n/a | |
| -$83.7M | -8.4x | 0.5x | |
| -$118M | -2.7x | 1.2x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Genomics & Personalized Medicine